U.S. SERIAL NO.: 08/458,978
FILED: June 2, 1995
AMENDMENT

cells are provided in an amount effective to inhibit smooth muscle cell proliferation at the site of the injury without migration of the vascular endothelial cells to the ~~arterial~~ endothelial cell of the blood vessel lining.

3. (twice amended) The method of claim 1 wherein the matrix is in a form selected from the group consisting of gels [or], foams, suspensions, microcapsules, solid polymeric supports, [or] and fibrous structures.

6. (twice amended) The method of claim 5 wherein the matrix is formed of a material selected from the group consisting of polyhydroxy acids, polyorthoesters, polyanhydrides, proteins, ~~carbohydrates~~ [or] ~~and~~ polysaccharides, polyphosphazenes, polyalkylene oxides and combinations thereof.

8. (twice amended) The method of claim 1 wherein the matrix further comprises biologically active compounds selected from the group consisting of [,] prostaglandins, prostanoids, [compounds regulating the renin-angiotensin axis,] tyrosine kinase inhibitors, immunosuppressants, glucocorticoids, anti-oxidants, free radical scavengers, peptide hormones, angiogenic factors, ~~and~~ angiogenic inhibitory factors, and combinations thereof.

11. (twice amended) A composition for inhibiting mechanisms involved in restenosis of a blood vessel having an endothelial cell lining following injury to ~~vascular tissue~~ the endothelial cell lining of the blood vessel in a patient in need of treatment thereof, comprising a biocompatible matrix shaped for implantation adjacent to a blood vessel, the matrix having seeded therein or thereon dissociated vascular endothelial cells, wherein the vascular endothelial cells are in an amount effective to inhibit smooth muscle cell

26

proliferation at the site of the injury without migration of the vascular endothelial cell to the ~~arterial~~ of the blood vessel lining.

13. (twice amended) The composition of claim 11 wherein the matrix is in a form selected from the group consisting of gels [or], foams, suspensions, microcapsules, solid polymeric supports, [or] and fibrous structures.

14. (amended) The composition of claim 11 wherein the cells are selected from the group consisting of autologous cells, allograft cells, and xenograft cells[, and genetically engineered cells].

16. (twice amended) The composition of claim 15 wherein the matrix is formed of a material selected from the group consisting of polyhydroxy acids, polyorthoesters, polyanhydrides, proteins, ~~carbohydrates~~ [or], polysaccharides, polyphosphazenes, and combinations thereof.

18. (twice amended) The composition of claim 11 wherein the matrix further comprises biologically active compounds selected from the group consisting of prostaglandins, prostanoids, [compounds regulating the renin-angiotensin axis,] tyrosine kinase inhibitors, immunosuppressants, glucocorticoids, anti-oxidants, free radical scavengers, peptide hormones, angiogenic factors, ~~and~~ angiogenic inhibitory factors, and combinations thereof.

Please add new claim 20.

~~20.~~ 19. (new) The composition of claim 14 wherein the cells are genetically engineered.

27